POLYPID LTD (PYPD) Fundamental Analysis & Valuation

NASDAQ:PYPD • IL0011326795

4.32 USD
+0.14 (+3.35%)
Last: Mar 10, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PYPD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, PYPD scores 2 out of 10 in our fundamental rating. PYPD was compared to 193 industry peers in the Pharmaceuticals industry. While PYPD seems to be doing ok healthwise, there are quite some concerns on its profitability. PYPD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. PYPD Profitability Analysis

1.1 Basic Checks

  • PYPD had negative earnings in the past year.
  • In the past year PYPD has reported a negative cash flow from operations.
  • PYPD had negative earnings in each of the past 5 years.
  • In the past 5 years PYPD always reported negative operating cash flow.
PYPD Yearly Net Income VS EBIT VS OCF VS FCFPYPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M

1.2 Ratios

  • With a Return On Assets value of -153.18%, PYPD is not doing good in the industry: 83.94% of the companies in the same industry are doing better.
  • PYPD's Return On Equity of -311.39% is on the low side compared to the rest of the industry. PYPD is outperformed by 75.65% of its industry peers.
Industry RankSector Rank
ROA -153.18%
ROE -311.39%
ROIC N/A
ROA(3y)-141.17%
ROA(5y)-134.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PYPD Yearly ROA, ROE, ROICPYPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • PYPD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYPD Yearly Profit, Operating, Gross MarginsPYPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PYPD Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for PYPD has been increased compared to 1 year ago.
  • PYPD has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PYPD has been reduced compared to a year ago.
PYPD Yearly Shares OutstandingPYPD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
PYPD Yearly Total Debt VS Total AssetsPYPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -19.17, we must say that PYPD is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -19.17, PYPD is doing worse than 82.38% of the companies in the same industry.
  • There is no outstanding debt for PYPD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.17
ROIC/WACCN/A
WACCN/A
PYPD Yearly LT Debt VS Equity VS FCFPYPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.97 indicates that PYPD should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.97, PYPD is doing worse than 60.62% of the companies in the same industry.
  • PYPD has a Quick Ratio of 1.82. This is a normal value and indicates that PYPD is financially healthy and should not expect problems in meeting its short term obligations.
  • PYPD has a Quick ratio (1.82) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.82
PYPD Yearly Current Assets VS Current LiabilitesPYPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PYPD Growth Analysis

3.1 Past

  • PYPD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.16%, which is quite impressive.
EPS 1Y (TTM)54.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • PYPD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.70% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.83%
EPS Next 2Y25.8%
EPS Next 3Y27.95%
EPS Next 5Y30.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PYPD Yearly Revenue VS EstimatesPYPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
PYPD Yearly EPS VS EstimatesPYPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. PYPD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PYPD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYPD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYPD Price Earnings VS Forward Price EarningsPYPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYPD Per share dataPYPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PYPD's earnings are expected to grow with 27.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.8%
EPS Next 3Y27.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PYPD Dividend Analysis

5.1 Amount

  • PYPD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PYPD Fundamentals: All Metrics, Ratios and Statistics

POLYPID LTD

NASDAQ:PYPD (3/10/2026, 8:00:01 PM)

4.32

+0.14 (+3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-12
Inst Owners28.35%
Inst Owner Change-95.08%
Ins Owners4.81%
Ins Owner ChangeN/A
Market Cap82.43M
Revenue(TTM)N/A
Net Income(TTM)-34.17M
Analysts82
Price Target12.5 (189.35%)
Short Float %0.24%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.29%
Min EPS beat(2)-21.99%
Max EPS beat(2)30.58%
EPS beat(4)2
Avg EPS beat(4)-4.31%
Min EPS beat(4)-39.67%
Max EPS beat(4)30.58%
EPS beat(8)4
Avg EPS beat(8)-6%
EPS beat(12)6
Avg EPS beat(12)1.33%
EPS beat(16)10
Avg EPS beat(16)3.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-62.26%
EPS NQ rev (3m)-62.26%
EPS NY rev (1m)-20.92%
EPS NY rev (3m)-9.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.51
P/tB 7.51
EV/EBITDA N/A
EPS(TTM)-2.26
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -153.18%
ROE -311.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.17%
ROA(5y)-134.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.82
Altman-Z -19.17
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)9.95%
Cap/Depr(5y)73.87%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.39%
EPS Next Y30.83%
EPS Next 2Y25.8%
EPS Next 3Y27.95%
EPS Next 5Y30.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.94%
OCF growth 3YN/A
OCF growth 5YN/A

POLYPID LTD / PYPD FAQ

What is the fundamental rating for PYPD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PYPD.


Can you provide the valuation status for POLYPID LTD?

ChartMill assigns a valuation rating of 1 / 10 to POLYPID LTD (PYPD). This can be considered as Overvalued.


Can you provide the profitability details for POLYPID LTD?

POLYPID LTD (PYPD) has a profitability rating of 0 / 10.


What is the expected EPS growth for POLYPID LTD (PYPD) stock?

The Earnings per Share (EPS) of POLYPID LTD (PYPD) is expected to grow by 30.83% in the next year.